These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 10780315

  • 1. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R.
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [Abstract] [Full Text] [Related]

  • 2. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 4. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 5. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study).
    Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M.
    Atherosclerosis; 2000 Jun; 150(2):429-36. PubMed ID: 10856536
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E, Muratti EN, Eliav O, Meiner V, Eisenberg S, Dann EJ, Sehayek E, Peters TK, Stein Y.
    Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E, Muratti EN, Eliav O, Peters TK.
    Am J Cardiol; 1995 Jul 13; 76(2):84A-88A. PubMed ID: 7604807
    [Abstract] [Full Text] [Related]

  • 9. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T, Tanabe K, Ishida H, Shimmura H, Ishikawa N, Goya N, Akiba T, Toma H.
    Transplant Proc; 2004 Sep 13; 36(7):2141-4. PubMed ID: 15518777
    [Abstract] [Full Text] [Related]

  • 10. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
    Liu L, Zhao SP, Zhou HN, Li QZ, Li JX.
    J Cardiovasc Pharmacol; 2007 Jul 13; 50(1):50-5. PubMed ID: 17666915
    [Abstract] [Full Text] [Related]

  • 11. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S, Gamez R, Mas R, Goicochea E.
    Int J Tissue React; 2003 Jul 13; 25(3):81-9. PubMed ID: 14756189
    [Abstract] [Full Text] [Related]

  • 12. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
    Hailer S, Pogarell O, Keller C, Wolfram G.
    Arzneimittelforschung; 1996 Sep 13; 46(9):879-83. PubMed ID: 8876936
    [Abstract] [Full Text] [Related]

  • 13. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 13; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR.
    Am J Cardiol; 2008 Feb 15; 101(4):490-6. PubMed ID: 18312764
    [Abstract] [Full Text] [Related]

  • 15. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 15; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 16. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
    Eliav O, Schurr D, Pfister P, Friedlander Y, Leitersdorf E.
    Am J Cardiol; 1995 Jul 13; 76(2):76A-79A. PubMed ID: 7604804
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE, Noll G, Hannak M, Lüscher TF.
    J Cardiovasc Pharmacol; 2000 Mar 13; 35(3):361-5. PubMed ID: 10710119
    [Abstract] [Full Text] [Related]

  • 18. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M.
    Circulation; 1993 Apr 13; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [Abstract] [Full Text] [Related]

  • 19. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A, MacMahon M, Barbir M, Wray R, Hunt BJ, Prescott RJ, Thompson GR.
    QJM; 1995 Jun 13; 88(6):421-7. PubMed ID: 7648234
    [Abstract] [Full Text] [Related]

  • 20. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct 13; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.